Plain-English translation of NCT06655259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combined approach for men newly diagnosed with metastatic prostate cancer—cancer that has spread beyond the prostate. You would first have a minimally invasive surgical procedure called TURP (transurethral resection of the prostate) to relieve urinary obstruction and reduce tumor burden, followed by hormone-blocking medications including androgen deprivation therapy combined with second-generation anti-androgen agents like abiraterone or enzalutamide. The researchers want to see whether this combination helps men live longer and stay free from cancer progression.
Currently, men with advanced prostate cancer are usually treated with hormone-blocking medications alone. This trial exists to find out whether adding a surgical procedure first to reduce tumor burden makes the hormone therapy more effective and improves outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would first undergo TURP, a surgical procedure to relieve urinary obstruction. After surgery, you would receive ongoing hormone-blocking medications as prescribed by your care team. You would have regular follow-up visits at Fudan University Cancer Hospital to monitor how you are responding to treatment, check for any side effects, measure your PSA levels, have imaging scans, and complete quality-of-life questionnaires. The study will track your progress for an extended period to see how long you remain free from cancer progression.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China